Evaluation of association between flu-like syndrome induced by Beta Interferon drug and required drug response in patients with Multiple sclerosis

Evaluation of association between flu-like syndrome induced by Beta Interferon drug and required drug response in patients with Multiple sclerosis

.

Bibliographic Details
Main Authors:	Abdollah Ghaferi, Maziar Shojaei, Arezoo Chouhdari
Format:	Article
Language:	English
Published:	Shahid Beheshti University of Medical Sciences 2019-08-01
Series:	Novelty in Biomedicine
Subjects:	multiple sclerosis .beta interferon .flu like drug side effect
Online Access:	http://journals.sbmu.ac.ir/nbm/article/view/23085

Similar Items

Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
by: Elmazny A, et al.
Published: (2020-03-01)

Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis
by: V. Byrnes, et al.
Published: (2006-01-01)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
by: Annette Kolb-Mäurer, et al.
Published: (2019-06-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
by: Masoud Mohammad Malekzadeh, et al.
Published: (2020-06-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
by: Ivanović Jovana, et al.
Published: (2019-01-01)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
by: Dian HE, et al.
Published: (2014-09-01)

Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient with Multiple Sclerosis Treated with Interferon-Beta
by: Pegah Sadat Fatehi, et al.
Published: (2018-11-01)

Fingolimod versus High Dose Interferon Beta-1a in Multiple Sclerosis: A Randomized Clinical Trial
by: Masoud Etemadifar, et al.
Published: (2017-02-01)

Higher Serum Uric Acid Levels in Multiple Sclerosis Patients After Longterm Interferon Beta Treatment
by: Toncev Gordana, et al.
Published: (2017-10-01)

Recurrent Arthritis and Anti-cyclic Citrullinated Peptide Positivity during Interferon-beta 1a Treatment in Two Patients with Multiple Sclerosis
by: Hamed Cheraghmakani, et al.
Published: (2016-09-01)

Beta-interferons in multiple sclerosis: A single center experience in India
by: Gupta Salil, et al.
Published: (2010-01-01)

Prospective study of thyroid functions in multiple sclerosis patients treated with interferon beta in Alexandria University MS clinic
by: Farouk Talaat, et al.
Published: (2021-02-01)

The Effect of Beta Interferon on the Expression of miR-145 in Patients with Multiple Sclerosis
by: Naeim Ehtesham, et al.
Published: (2016-11-01)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
by: Miraç Ayşen Ünsal
Published: (2019-03-01)

Comparison Of The Expression Of MiR-326 Between Interferon Beta Responders And Non-Responders In Relapsing-Remitting Multiple Sclerosis
by: Mahtab Fattahi, et al.
Published: (2020-04-01)

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis
by: Dário Júnior de Freitas Rosa, et al.
Published: (2011-04-01)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016-11-01)

Uncommon presentation of morphea related to interferon beta in a patient with concomitant multiple sclerosis and chronic hepatitis C: A case report
by: Mrinal Gupta, et al.
Published: (2020-09-01)

A Case Report of Vasculitis Necrotizing after Interferon beta-1b Injection in Multiple Sclerosis
by: Mehrdokht Mazdeh
Published: (2005-09-01)

Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial
by: Fereshteh Ashtari, et al.
Published: (2011-01-01)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart® in patients with multiple sclerosis
by: Edo Solsona MD, et al.
Published: (2017-03-01)

Efficacy and safety of the new drug against multiple sclerosis «PEGylated Interferon beta-1a Human» in monkeys compared with unmodified interferon beta-1a
by: N. A. Spirina, et al.
Published: (2018-02-01)

MicroRNA Expression Changes during Interferon-Beta Treatment in the Peripheral Blood of Multiple Sclerosis Patients
by: Georg Füllen, et al.
Published: (2013-08-01)

Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review
by: Gita Faghihi, et al.
Published: (2015-01-01)

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Detection of Binding Anti-Drug Antibodies against Interferon Beta
by: Kathleen Ingenhoven, et al.
Published: (2017-07-01)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
by: Hendin B, et al.
Published: (2018-07-01)

Isoniazid-induced flu-like syndrome: A rare side effect
by: Sudipta Pandit, et al.
Published: (2013-01-01)

Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription
by: Keivan Basiri, et al.
Published: (2012-02-01)

Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription
by: Amir Hadi Maghzi, et al.
Published: (2012-02-01)

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority
by: Silvia Romano, et al.
Published: (2019-07-01)

Development of rheumatoid arthritis during treatment of multiple sclerosis with interferon beta 1-a. Coincidence of two conditions or a complication of treatment: A case report
by: Seyed Mohammad Masood Hojjati, et al.
Published: (2016-09-01)

A prospective study comparing injectable interferon beta-1a (Rebif 22-44), (Avonex 30) and 1b (Betaseron 250) injection site reaction in multiple sclerosis patients
by: Foziah Jabbar Alshamrani, et al.
Published: (2019-09-01)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
by: Masoud Etemadifar, et al.
Published: (2011-01-01)

Sleep Quality in Patients with Multiple Sclerosis
by: Arash Mosarrezaii, et al.
Published: (2019-01-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Diplopia Associated with Interferon-b1a Treatment: Report of a Case
by: Özge Saraç
Published: (2011-09-01)

Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis
by: Martina Novotna, et al.
Published: (2020-09-01)

Interferon Beta: Analysis of Information on Adverse Reactions and Evaluation of Possibility of Signal Identification
by: K. E. Zatolochina, et al.
Published: (2019-06-01)

Flu Days
by: Peter Makuck
Published: (2016-12-01)

Innate Immunity in Systemic Sclerosis – Role of Toll-Like Receptors, Interferon, and the Potential Impact of Vitamin D
by: Ruxandra Ionescu, et al.
Published: (2014-07-01)